FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 171.93

Change

+0.94 (+0.55)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B

ETFs Containing FBT

FBT:CA First Trust NYSE Arca Bio.. 99.96 % 0.00 %

+0.24 (+0.84%)

CAD 1.83M
FHM:CA 99.89 % 0.78 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.78% 40% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.78% 36% F 43% F
Trailing 12 Months  
Capital Gain 18.52% 26% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.52% 26% F 46% F
Trailing 5 Years  
Capital Gain 42.00% 36% F 66% D+
Dividend Return 1.83% 36% F 5% F
Total Return 43.83% 36% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 1.30% N/A N/A 43% F
Dividend Return 1.63% N/A N/A 33% F
Total Return 0.33% N/A N/A 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.22% N/A N/A 72% C
Risk Adjusted Return 13.35% N/A N/A 33% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike